Issues (Archived 12/09/2011)
Sixth Annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer
The Office of Intramural Research, Office of the Director, NIH, invites you to the sixth annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer. The lecture will be held on Friday, December 9, 2011, at 9:30 AM in the Masur Auditorium, Building 10, NIH campus in Bethesda, Maryland.
Dr. Ira Pastan will present “Treatment of Cancer with Recombinant Immunotoxins: From Technology Transfer to the Patient.” Dr. Pastan is an NIH Distinguished Investigator and Chief, Laboratory of Molecular Biology, NCI-CCR.
To watch the lecture online, please visit http://videocast.nih.gov.
Individuals with disabilities who need Sign Language Interpreters and/or reasonable accommodation to participate in this event should contact Joe Kleinman at 301-496-0472 and/or the Federal Relay (1-800-877-8339). Requests should be made at least 5 days in advance of the event.
Issues (Archived 12/09/2011)
Technology Licensing Specialist Position Available
The NIH Office of Technology Transfer has a position open for a Technology Licensing Specialist. Details are available in the job announcements posted at http://www.usajobs.gov/GetJob/ViewDetails/303953800 (for all U.S. citizens) and http://www.usajobs.gov/GetJob/ViewDetails/303991200 (for Status candidates, Veterans Employment Opportunity Act eligibles).
Issues (Archived 11/25/2011)
Program Specialist Position Available
The NIH Office of Technology Transfer has a position open for a Program Specialist. Details are available in the job announcement posted at http://www.usajobs.gov/GetJob/ViewDetails/303499700.
Issues (Archived 11/21/2011)
Obama Announces New Directives to Accelerate Technology Transfer and Commercialization — NIH Launches Expedited Start-Up License Agreements
In support of his "Startup-America" initiative, President Obama announced a new directive today committing each Federal agency conducting research and development to increasing the successful outcomes of technology transfer and commercialization activities significantly over the next five years. Actions from the directive include establishing goals and measuring performance, streamlining administrative processes, and facilitating local and regional partnerships. NIH is committed to these directives and has announced an important initiative, Start-Up License Agreements, in support of the directive to streamline administrative processes.
The NIH, through the Office of Technology Transfer, is offering a set of Start-Up License Agreements drafted to expedite the transfer of NIH and FDA owned patents for drugs and biologics under terms that are favorable to companies in a start-up phase. Companies can qualify for the licenses if they are less than 5 years old, have raised less than $5M in capital, and have fewer than 50 employees. NIH is offering an exclusive Start-Up Evaluation License Agreement for one year for a fee of only $2,000, which can be converted to a Start-up Exclusive Commercial License Agreement. Visit our Start-up webpage to learn more.
Issues (Archived 11/21/2011)
NIH Joins New Consortium for Neglected Tropical Diseases, Malaria & Tuberculosis Product Development
The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies, BIO Ventures for Global Health (BVGH) and NIH, has launched WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and tuberculosis.
According to the World Health Organization (WHO), neglected tropical diseases today impair the lives of an estimated 1 billion people. By providing a searchable, public database of available intellectual property assets, information, and resources, WIPO Re:Search facilitates new partnerships with organizations that conduct research on treatments for neglected tropical diseases, malaria, and tuberculosis.
The founding eight pharmaceutical companies, WIPO, BVGH, and NIH are joined by a distinguished group of globally recognized institutions as providers, potential users, and supporters of WIPO Re:Search. BVGH will manage the WIPO Re:Search Partnership Hub, which will facilitate relationships between the pharmaceutical company providers and new users.
More information about the new WIPO Re:Search Partnership and how to access it can be found here.
Issues (Archived 11/21/2011)
Intramural Research Training Award (IRTA) Fellowship Opportunity Available
The NIH Office of Technology Transfer is now accepting applications for an IRTA Fellowship position. This fellowship will enable a qualified candidate to combine their science background with training and experience in the technology transfer field. Fellows work with OTT marketing, patenting, and licensing staff, as well as researchers and technology and business development people within and outside NIH. Details about the program may be found at http://www.ott.nih.gov/about_nih/IRTA.aspx.
Issues (Archived 11/16/2011)
New NINDS Funding Opportunity Announcement
The National Institute of Neurological Disorders and Stroke (NINDS) released a Funding Opportunity Announcement (FOA) through the NINDS SBIR Technology Transfer (SBIR-TT) Program encouraging Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to transfer technology out of the NIH intramural research labs into the private sector.
The next submission date for the SBIR application is December 5, 2011.
SBCs are encouraged to submit a license application to the NIH Office of Technology Transfer (OTT) before submitting an SBIR application. The application can be obtained at: http://www.ott.nih.gov/forms_model_agreements/forms_model_agreements.aspx#MLA. This completed license application should be emailed with a subject line that includes “SBIR-TT” to OTT-SBIR@mail.nih.gov. The SBC will receive a letter of confirmation for the submitted license application that it can include in the Letters of Support section of the PHS 398 Research Plan.
Issues (Archived 11/04/2011)
New SBIR Funding Opportunities in Cancer
The National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases are currently soliciting proposals for three contract funding opportunities in cancer technologies through the SBIR-TT Program. Details on each proposal may be found by clicking on the individual Contract Topics below.
The deadline for receipt of all FY2012-1 contract topic proposals is November 7, 2011.
A public briefing will be held on Friday, October 7, 2011, 10:00AM-1:00PM, in Room A of the Natcher Building, the National Institutes of Health, Bethesda, Maryland. Written questions may be submitted in advance to Ms. Anita Hughes, NCI Office of Acquisitions, at firstname.lastname@example.org. Interested parties can participate in person or via a live webinar. Webinar information may be found at http://www.sbir.cancer.gov/news/upcoming/webinar_signup.asp.
To view a listing of Frequently Asked Questions related to the three funding opportunities noted above, click here.
Additional SBIR resources related to these funding opportunities are noted below:
Issues (Archived 10/04/2011)
NIH to Host “Technology Transfer Summit North America” on October 3-4, 2011
The NIH campus in Bethesda, MD will be the site of the next Tech Transfer Summit North America (TTSNA), the leading early-stage biotech partnering, licensing, venture and innovation platform, co-hosted and co-sponsored by the NIH Office of Technology Transfer, TTS Ltd. and regional host partners such as BIO Maryland, Johns Hopkins University and the Maryland Biotechnology Center. The conference will take place on October 3-4 at NIH’s Masur Auditorium in Building 10, 9000 Rockville Pike, Bethesda, MD 20892.
TTSNA is one of a series of summits held within the Global Tech Transfer Initiative and is designed specifically to put innovators, early-stage SMEs and technology managers from leading universities and research institutes together with biotech & pharma licensing & business development executives, VCs, serial entrepreneurs, and leading IP specialists for interactive sessions relating to partnering, licensing & business development. The TTSNA conference in Bethesda will feature speakers such as James C. Greenwood, BIO President & CEO, along with representatives from NIH, Merck, Pfizer, Shire, Novartis, JPMorgan, Columbia, Cornell, Johns Hopkins and other leading life science organizations.
More details about the conference including registration information and the conference agenda can be found by clicking here: Tech Transfer Summit North America. You may also enter the Partner Code “MBE12” to register with a 40% discount which gives specially discounted registration rates of $329 for academics/non-profit and $539 for industry attendees.
Issues (Archived 8/16/2011)
OTT Contributes To New AUTM Technology Transfer Practice Manual Volume
Chapters from several staff members of the NIH Office of Technology Transfer are featured in the latest volume of the AUTM Technology Transfer Practice Manual, 3rd Edition, published by the Association of University Technology Managers (AUTM). For many years this publication has been considered a popular and critical reference tool for academic and federal technology transfer professionals of all levels and backgrounds. The just-released Volume Four: Managing Complex / Special Issues covers some of the more in-depth or advanced technology transfer and licensing topics in the field.
Included in the new volume are:
“Research Tools Policies and Practices: Perspective of a Public Institution” contributed by Uri Reichman, MBA, PhD, OTT Senior Advisor for Licensing, Susan E. Ano, PhD, OTT Branch Chief, Infectious Disease and Medical Engineering and Steven M. Ferguson, MBA, CLP, OTT Deputy Director, Licensing and Entrepreneurship. Please click here for access to this chapter.
“Research Discoveries after Kubin” contributed by Nancy W. Vensko, JD, Partner with Fitch, Even, Tabin & Flannery and Steven M. Ferguson, MBA, CLP, OTT Deputy Director, Licensing and Entrepreneurship. Please click here for access to this chapter.
Issues (Archived 8/12/2011)
Use of Pay.gov Expedites Research Tools To Licensees
With its introduction earlier this year, NIH licensees have found that using the new royalty payment site within Pay.gov expedites processing times for shipment of their research tools licensed from the NIH and FDA intramural research programs. The value of such time savings to corporate R&D programs is not trivial since waiting too long to secure research materials or tools can delay or sink a critical drug development program or other business venture. By eliminating the need for bank checks, the bank-to-bank transfer system at Pay.gov has shortened the processing time for research tool and other license agreements from several months down to a day or less. For example, a recent transaction for baculovirus vectors at NIH was indeed processed in a single afternoon allowing for almost instantaneous release of the licensed materials from the inventors laboratory.
Companies looking to save time on their royalty transactions with NIH can easily pay royalties on Pay.gov by going to https://www.pay.gov and clicking on NIH in the agency list. Comments received to date from licensees who have started to use Pay.gov include:
– "For pay.gov, it's easy, convenient and fast, I guess that’s what I experienced."
– "It literally only took me about 5 minutes after reading the email/letter to process payment. Great service!"
– "I just completed sending all the MAR payments and it was great! I am glad I decided to try the system."
Pay.gov itself is a multifaceted web-based application allowing anyone to make Automated Clearing House (ACH) payments to government agencies by debit from a checking or savings account. Pay.gov was launched in 2000 and is maintained by the U.S. Department of the Treasury.
Pay.gov is open 24-7, and is encouraged for use in all types of royalty payments with NIH.
Issues (Archived 7/28/2011)
OTT iPhone app wins NIH award!
Ajoy Prabhu, the Head of Marketing Operations for the NIH Office of Technology of Technology Transfer, won an NIH award celebrating plain language and clear communication for the iPhone/iPad app he developed. The app provides real-time information on NIH and Food and Drug Administration technologies available for licensing and NIH Cooperative Research and Development (CRADA) opportunities. The app can be downloaded at http://itunes.apple.com/us/app/nih-ott-licensing-opportunities/id401257307.
Issues (Archived 7/28/2011)
NIH’s Mojdeh Bahar Elected FLC Chair!
Mojdeh Bahar, Chief of the Cancer Branch at the NIH Office of Technology Transfer, was elected Chair of the Federal Laboratory Consortium for Technology Transfer (FLC) at the 2011 FLC National Meeting. The FLC is the nationwide network of federal laboratories that provides the forum to develop strategies and opportunities for linking laboratory mission technologies and expertise with the marketplace. Ms. Bahar previously served as the FLC’s Regional Coordinator for the Mid-Atlantic Region which encompasses federal R&D assets located in Pennsylvania, Delaware, Maryland, Virginia, West Virginia, and the District of Columbia. Information about the FLC can be found at http://www.federallabs.org/.
Issues (Archived 5/06/2011)
NIH OTT Annual Report for FY10 is now available for download!
The OTT is pleased to announce that the annual report for Fiscal Year 2010 is now available for downloading. In trying to keep up with the innovative spirit, the FY10 report includes a completely redesigned format complete with links to interactive graphs and charts found on the OTT website. Click the icon below to start the to download and view the report.
Issues (Archived 2/25/2011)
NIH Makes Its March-In Determination In The Case Of Fabrazyme®
NIH announces its determination not to use, at this time, its Bayh Dole Act march-in authority. The Determination, however, includes certain conditions and actions required of Mount Sinai School of Medicine and the Genzyme Corporation.
Based upon the information currently available, NIH has determined that a march-in proceeding is not warranted at the present time because any licensing plan that might result from such a proceeding would not address the problem of access to Fabrazyme®. NIH has no information that a company is expecting imminent FDA approval for a competing version covered by Mount Sinai’s patent; the patent is not an obstacle for a company to conduct clinical trials; and Genzyme has indicated that it expects the production of Fabrazyme® to be back to full supply levels in the first half of 2011.
NIH remains concerned about the health of Fabry patients and their inability to access Fabrazyme®. While the exercise of march-in would not immediately resolve the lack of access to Fabrazyme®, NIH will continue to monitor the shortage of Fabrazyme® and will immediately re-evaluate this decision upon receiving any information that suggests progress toward restoring the supply of Fabrazyme® to meet patient demand is not proceeding as represented. If at any time new information becomes available relevant to the use of march-in, it will be evaluated it as quickly as possible to determine whether the use of that authority is warranted.
The complete March-In Determination can be found at: http://www.ott.nih.gov/policy/March-in-Fabrazyme.pdf